Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023
Class II · Moderate risk

Simvastatin USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0727-30 D-0558-2023
Class III · Low risk

Norepinephrine Bitartrate Injection

Failed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product monitoring.

Terminated Impurity / degradation Sun Pharmaceutical Industries INC NDC 47335-615-40 D-0529-2023
Class II · Moderate risk

Isopropyl Alcohol Antiseptic 75%

CGMP deficiencies: Product manufactured at the same site where FDA testing found Presence of methanol in other products.

Terminated Chemical / undeclared Jarman's Midwest Cleaning Systems, Inc. D-0872-2023
Class III · Low risk

Bevacizumab 2.5 mg/0.1 mL

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Terminated Labeling / mix-up Pine Pharmaceuticals, LLC NDC 69194-0458-1 D-0531-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023

Recalls by year